Table 1 Basic characteristics stratified by BRCAness status (n = 121).
From: BRCAness as a prognostic indicator in patients with early breast cancer
BRCAness (n = 48) | Non-BRCAness (n = 73) | P value | |
|---|---|---|---|
Age at diagnosis | |||
Range | 27–74 | 31–75 | 0.268 |
Mean | 48.0 | 49.1 | |
Tumor size | |||
T1 | 9 (18.8) | 14 (19.2) | 0.949 |
T2 | 28 (58.3) | 39 (53.4) | |
T3 | 6 (12.5) | 11 (15.1) | |
T4 | 5 (10.4) | 9 (12.3) | |
Lymph node status | |||
N0 | 27 (56.2) | 34 (46.6) | 0.065 |
N1 | 16 (33.3) | 37 (50.7) | |
N2 | 5 (10.4) | 2 (2.7) | |
TNM stage | |||
I | 8 (16.7) | 9 (12.3) | 0.743 |
II | 28 (58.3) | 47 (64.4) | |
III | 12 (25.0) | 17 (23.3) | |
Nuclear grade | |||
I | 2 (4.3) | 24 (38.7) | < 0.001a |
II | 9 (19.6) | 8 (12.9) | |
III | 35 (76.1) | 30 (48.4) | |
Hormone receptor status | |||
Positive | 2 (4.2) | 36 (49.3) | < 0.001a |
Negative | 46 (95.8) | 37 (50.7) | |
HER2 status | |||
Positive | 2 (4.2) | 10 (13.7) | 0.122 |
Negative | 46 (95.8) | 63 (86.3) | |
Molecular subtype | |||
Luminal | 2 (4.2) | 36 (49.3) | < 0.001a |
HER2 | 2 (4.2) | 6 (8.2) | |
TNBC | 44 (91.6) | 31 (42.5) | |
